文献速递肝病

自身免疫性肝炎患者COVID-19结局:国际多中心研究

Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.
PubMed 文献 · Hepatology · 2021-01-01

该回顾性多中心研究纳入欧洲和美洲34个中心的110例自身免疫性肝炎(AIH)合并COVID-19患者,分析重症COVID-19(需机械通气、ICU入住和/或死亡)相关因素,并与倾向评分匹配的无AIH但患慢性肝病(CLD)的COVID-19患者比较。结果显示AIH患者重症COVID-19率和全因死亡率与非AIH CLD患者无差异,肝硬化是AIH患者重症COVID-19的独立预测因素,持续免疫抑制与较低的新发肝损伤风险相关。

要点

  • AIH患者重症COVID-19率和死亡率与非AIH慢性肝病患者无显著差异。
  • 肝硬化是AIH患者发生重症COVID-19的最强独立预测因素。
  • 持续免疫抑制不增加重症COVID-19风险,且降低新发肝损伤风险。

核心结论

  • AIH患者COVID-19结局不劣于其他原因慢性肝病患者,肝硬化是重症COVID-19的最强预测因素。
  • 持续免疫抑制不增加重症COVID-19风险,但降低COVID-19期间新发肝损伤风险。

研究设计与样本

  • 回顾性研究,纳入欧洲和美洲34个中心的110例AIH合并COVID-19患者(80%女性,中位年龄49岁,范围18-85岁)。
  • 与倾向评分匹配的无AIH但患慢性肝病(CLD)的COVID-19患者队列比较。

主要发现

  • 新发肝损伤(丙氨酸氨基转移酶>2倍正常上限)发生率为37.1%(33/89)。
  • 抗病毒药物使用与肝损伤相关(P=0.041;OR,3.36;95%CI,1.05-10.78)。
  • 持续免疫抑制与较低肝损伤发生率相关(P=0.009;OR,0.26;95%CI,0.09-0.71)。
  • AIH与非AIH CLD患者重症COVID-19率(15.5% vs 20.2%,P=0.231)和全因死亡率(10% vs 11.5%,P=0.852)无差异。
  • 肝硬化是AIH患者重症COVID-19的独立预测因素(P<0.001;OR,17.46;95%CI,4.22-72.13)。

临床怎么用

  • AIH患者感染COVID-19时,持续免疫抑制治疗不增加重症风险,且可能降低新发肝损伤风险。
  • 合并肝硬化的AIH患者应被视为重症COVID-19高危人群,需加强监测。

局限性

  • 回顾性研究设计。
  • 样本量有限(110例AIH患者)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking. APPROACH AND RESULTS: We performed a retrospective study on patients with AIH and COVID-19 from 34 centers in Europe and the Americas. We analyzed factors associated with severe COVID-19 outcomes, defined as the need for mechanical ventilation, intensive care admission, and/or death. The outcomes of patients with AIH were compared to a propensity score-matched cohort of patients without AIH but with chronic liver diseases (CLD) and COVID-19. The frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 × the upper limit of normal) during COVID-19 was also evaluated. We included 110 patients with AIH (80% female) with a median age of 49 (range, 18-85) years at COVID-19 diagnosis. New-onset liver injury was observed in 37.1% (33/89) of the patients. Use of antivirals was associated with liver injury (P = 0.041; OR, 3.36; 95% CI, 1.05-10.78), while continued immunosuppression during COVID-19 was associated with a lower rate of liver injury (P = 0.009; OR, 0.26; 95% CI, 0.09-0.71). The rates of severe COVID-19 (15.5% versus 20.2%, P = 0.231) and all-cause mortality (10% versus 11.5%, P = 0.852) were not different between AIH and non-AIH CLD. Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P < 0.001; OR, 17.46; 95% CI, 4.22-72.13). Continuation of immunosuppression or presence of liver injury during COVID-19 was not associated with severe COVID-19. CONCLUSIONS: This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Efe C, Dhanasekaran R, Lammert C, et al. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology. 2021. PMID: 33713486. doi:10.1002/hep.31797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。